

**RECEIVED
CENTRAL FAX CENTER
OCT 27 2004**

Attorney Docket No.: 5367.230-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Knudsen et al

Serial No.: 10/730,215

Group Art Unit: 1636

Filed: December 8, 2003

Examiner: McKelvey, Terry Alan

For: GLP-2 Derivatives

**CERTIFICATE OF FACSIMILE TRANSMISSION
703-872-9306**

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

1. Amendment

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner McKelvey, Terry Alan, fax number (703) 872-9306.

Respectfully submitted,

Date: October 27, 2004

Csaba Atila Szakolczai
Csaba Atila Szakolczai
Novo Nordisk® Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

**RECEIVED
CENTRAL FAX CENTER
OCT 27 2004**

**PATENT
Attorney Docket No. 5367.230-US**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Knudsen et al.

Application No. 10/730,215

Group Art Unit: 1636

Filed: December 8, 2003

Examiner: McKelvey, Terry Alan

For: GLP-2 DERIVATIVES

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Prior to further consideration of the above-referenced patent application, please amend the application and consider the provided remarks as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are reflected in the **Listing of Claims**, which begins on page 7 of this paper.

Remarks concerning the amendments begin on page 10 of this paper.